RA0462

antibody from Oursmab

Targeting: LIF CDF, DIA, HILDA

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0462

Provider

Oursmab

Product name

Falbikitug (Biosimilar Reference Antibody) (LIF)

Antibody type

Monoclonal

Description

Falbikitug is an investigational, humanized immunoglobulin G1 (IgG1) monoclonal antibody developed for the treatment of solid tumors. It functions as a targeted inhibitor of leukemia inhibitory factor (LIF), a cytokine in the tumor microenvironment. By binding to LIF with high affinity, falbikitug neutralizes its activity, blocking its interaction with the LIF receptor (LIFR) and the co-receptor gp130 on target cells. This blockade inhibits the downstream JAK/STAT signaling pathway, which is associated with multiple tumor-promoting processes. As a result, falbikitug exerts potential immunomodulating and anti-tumor effects, including reversing immunosuppression, inhibiting cancer stem cell self-renewal, and enhancing the efficacy of other cancer therapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.